Contact
Please use this form to send email to PR contact of this press release:
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
TO:
Please use this form to send email to PR contact of this press release:
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
TO: